CV0501

CV0501 is a COVID-19 mRNA vaccine candidate developed in collaboration between CureVac and GSK. It is based on CureVac's advanced second-generation mRNA backbone using chemically modified mRNA. The vaccine encodes the prefusion stabilized full-length spike protein of the SARS-CoV-2 Omicron variant BA.1 and is formulated with lipid nanoparticles (LNPs). CV0501 was designed with specifically optimized non-coding regions to deliver improved mRNA translation for increased and extended protein expression compared to the first-generation mRNA backbone. Clinical trials have shown that CV0501 is generally well tolerated and induces immune responses not only against the Omicron BA.1 subvariant but also against the original SARS-CoV-2 variant, the Delta variant, and other Omicron subvariants.